JPH07507557A - ヒトにおけるリンパ球結合を仲介する新規な内皮細胞分子 - Google Patents
ヒトにおけるリンパ球結合を仲介する新規な内皮細胞分子Info
- Publication number
- JPH07507557A JPH07507557A JP6501155A JP50115594A JPH07507557A JP H07507557 A JPH07507557 A JP H07507557A JP 6501155 A JP6501155 A JP 6501155A JP 50115594 A JP50115594 A JP 50115594A JP H07507557 A JPH07507557 A JP H07507557A
- Authority
- JP
- Japan
- Prior art keywords
- vap
- antibody
- binding
- cells
- endothelial cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.実質的に精製され単離された内皮血管接着タンパク質−1(VAP−1)。 2.該VAP−1がヒトVAP−1である請求の範囲第1項記載のVAP−1。 3.該VAP−1がアミノ酸配列TEDGDMXLVNGASANEGXVE[ 配列番号:1]からなる請求の範囲第1または2項記載のVAP−1。 4.該VAP−1が90kDaの分子量をもつ請求の範囲第1、2または3項記 載のVAP−1。 5.該VAP−1がリンパ球と結合する請求の範囲第1、2、3または4項記載 のVAP−1。 6.該VAP−1が、抗VAP−1抗体と該VAP−1を結合することからなる 方法によってえられる請求の範囲第1、2、3、4または5項記載のVAP−1 。 7.抗VAP−1抗体を産生するハイブリドーマ細胞系。 8.受託番号がDSM ACC2041である請求の範囲第7項記載のハイブリ ドーマ細胞系。 9.抗VAP−1抗体または該抗VAP−1抗体の結合断片がヒト内皮VAP− 1に特異的であり、該抗体がヒト■静脈内皮細胞(HUVEC)表面タンパクと 結合しない、該抗体、または該結合断片。 10.請求の範囲第8項記載の細胞系によって産生される、血管接着タンパク質 VAP−1と特異的に結合するモノクローナル抗体1B2。 11.抗VAP−1抗体または該抗VAP−1抗体の結合断片からなる、細胞を 含まない組成物。 12.有効量の請求の範囲第9または10項記載の抗VAP−1抗体からなり、 注射に適した剤形である医薬組成物。 13.単位投与量の形である請求の範囲第12項記載の医薬組成物。 14.VAP−1が仲介するリンパ球との内皮細胞の結合を拮抗する方法であっ て、該方法がVAP−1が仲介するリンパ球−内皮細胞接着反応に関与するVA P−1内皮細胞部位をブロックするのに充分な量のVAP−1結合合成物を与え ることによって、前記反応を阻害することからなる方法。 15.該VAP−1結合合成物が抗VAP−1抗体である請求の範囲第14項記 載の方法。 16.該抗VAP−1抗体がポリクローナル抗体である請求の範囲第15項記載 の方法。 17.該抗VAP−1抗体がモノクローナル抗体である請求の範囲第15項記載 の方法。 18.該モノクローナル抗体がモノクローナル抗体1B2である請求の範囲第1 7項記載の方法。 19.該VAP−1が仲介するリンパ球−内皮細胞接着反応の該阻害が患者にお いてインビボで生じる請求の範囲第14項記載の方法。 20.該リンパ球−内皮細胞接着反応が炎症(慢性または急性)、関節炎、リウ マチ様関節炎、感染症、皮膚疾患、炎症性腸疾患および自己免疫疾患からなる群 から選択される疾患と結びつく請求の範囲第19項記載の方法。 21.該VAP−1が仲介するリンパ球−内皮細胞接着反応の該阻害がインビト ロで生じる請求の範囲第14項記載の方法。 22.VAP−1が仲介するリンパ球との内皮細胞の結合を患者において診断す る方法であって、該方法がVAP−1が仲介するリンパ球内皮細胞接着反応に関 与するVAP−1内皮細胞部位をブロックするのに充分な量のVAP−1結合合 成物を投与することによって、該患者における前記反応を阻害することからなる 方法。 23.該VAP−1結合合成物が抗VAP−1抗体である請求の範囲第22項記 載の方法。 24.該抗VAP−1抗体がポリクローナル抗体である請求の範囲第23項記載 の方法。 25.該抗VAP−1抗体がモノクローナル抗体である請求の範囲第23項記載 の方法。 26.該モノクローナル抗体がモノクローナル抗体1B2である請求の範囲第2 5項記載の方法。 27.該リンパ球−内皮細胞接着反応が炎症(慢性または急性)、関節炎、リウ マチ様関節炎、感染症、皮膚疾患、炎症性腸疾患および自己免疫疾患からなる群 から選択される疾患と結びつく請求の範囲第22項記載の方法。 28.VAP−1が仲介するリンパ球との内皮細胞の結合によって仲介される患 者における医療状態を診断する方法であって、 (1)VAP−1陽性細胞であろうと思われる該患者からの細胞を採取すること 、 (2)工程(1)の該細胞を抗VAP−1抗体にさらすこと、 (3)該VAP−1陽性細胞との抗VAP−1抗体結合を検出すること、 (4)該結合の量にもとづいて該医療状態を診断することからなる該方法。 29.該抗VAP−1抗体がポリクローナル抗体である請求の範囲第28項記載 の方法。 30.該抗VAP−1抗体がモノクローナル抗体である請求の範囲第28項記載 の方法。 31.該モノクローナル抗体がモノクローナル抗体1B2である請求の範囲第3 0項記載の方法。 32.該医療状態が炎症(慢性または急性)、関節炎、リウマチ様関節炎、感染 症、皮膚疾患、炎症性腸疾患および自己免疫疾患からなる群から選択される疾患 である請求の範囲第28項記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89535492A | 1992-06-09 | 1992-06-09 | |
US895,354 | 1992-06-09 | ||
PCT/FI1993/000250 WO1993025582A1 (en) | 1992-06-09 | 1993-06-09 | A novel endothelial cell molecule mediating lymphocyte binding in man |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002289280A Division JP3500384B2 (ja) | 1992-06-09 | 2002-10-01 | ヒトにおけるリンパ球結合を仲介する新規な内皮細胞分子 |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH07507557A true JPH07507557A (ja) | 1995-08-24 |
JP3431922B2 JP3431922B2 (ja) | 2003-07-28 |
Family
ID=25404388
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP50115594A Expired - Lifetime JP3431922B2 (ja) | 1992-06-09 | 1993-06-09 | 炎症性疾患および自己免疫疾患の診断用組成物および診断方法 |
JP2002289280A Expired - Lifetime JP3500384B2 (ja) | 1992-06-09 | 2002-10-01 | ヒトにおけるリンパ球結合を仲介する新規な内皮細胞分子 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002289280A Expired - Lifetime JP3500384B2 (ja) | 1992-06-09 | 2002-10-01 | ヒトにおけるリンパ球結合を仲介する新規な内皮細胞分子 |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0656906B1 (ja) |
JP (2) | JP3431922B2 (ja) |
KR (1) | KR100268772B1 (ja) |
AT (1) | ATE184315T1 (ja) |
AU (1) | AU671837B2 (ja) |
CA (1) | CA2137551C (ja) |
DE (1) | DE69326347T2 (ja) |
DK (1) | DK0656906T3 (ja) |
ES (1) | ES2135480T3 (ja) |
FI (1) | FI121176B (ja) |
GR (1) | GR3031255T3 (ja) |
HU (1) | HU217175B (ja) |
NZ (2) | NZ299958A (ja) |
WO (1) | WO1993025582A1 (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2204838C2 (ru) * | 1997-05-23 | 2003-05-20 | Байотай Терапис Лтд. | Сосудистый белок - 1 адгезии, обладающий аминооксидазной активностью |
FI20020807A0 (fi) * | 2002-04-29 | 2002-04-29 | Biotie Therapies Oyj | Uusia humanisoituja anti-VAP-1 monoklonaalisia vasta-aineita |
FI20061156A0 (fi) | 2006-12-27 | 2006-12-27 | Elina Kivi | Uusia peptidejä |
FI20075278A0 (fi) * | 2007-04-20 | 2007-04-20 | Biotie Therapies Corp | Uudet täysin ihmisperäiset anti-VAP-1 monoklonaaliset vasta-aineet |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69406664T2 (de) * | 1993-06-18 | 1998-06-04 | Biotie Therapies Oy | Zusammensetzungen und diagnostische verfahren unter verwendung von monoklonalen antikoerpern gegen cd44v6 |
-
1993
- 1993-06-09 JP JP50115594A patent/JP3431922B2/ja not_active Expired - Lifetime
- 1993-06-09 DK DK93913035T patent/DK0656906T3/da active
- 1993-06-09 DE DE69326347T patent/DE69326347T2/de not_active Expired - Lifetime
- 1993-06-09 AT AT93913035T patent/ATE184315T1/de active
- 1993-06-09 NZ NZ299958A patent/NZ299958A/en not_active IP Right Cessation
- 1993-06-09 EP EP93913035A patent/EP0656906B1/en not_active Expired - Lifetime
- 1993-06-09 KR KR1019940704502A patent/KR100268772B1/ko not_active IP Right Cessation
- 1993-06-09 AU AU43281/93A patent/AU671837B2/en not_active Expired
- 1993-06-09 WO PCT/FI1993/000250 patent/WO1993025582A1/en active Application Filing
- 1993-06-09 NZ NZ253151A patent/NZ253151A/en not_active IP Right Cessation
- 1993-06-09 ES ES93913035T patent/ES2135480T3/es not_active Expired - Lifetime
- 1993-06-09 CA CA002137551A patent/CA2137551C/en not_active Expired - Lifetime
- 1993-06-09 HU HU9403516A patent/HU217175B/hu unknown
-
1999
- 1999-09-20 GR GR990402349T patent/GR3031255T3/el unknown
-
2002
- 2002-10-01 JP JP2002289280A patent/JP3500384B2/ja not_active Expired - Lifetime
-
2009
- 2009-03-16 FI FI20095269A patent/FI121176B/fi not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
DE69326347D1 (de) | 1999-10-14 |
KR100268772B1 (ko) | 2000-10-16 |
NZ299958A (en) | 2000-07-28 |
AU4328193A (en) | 1994-01-04 |
DE69326347T2 (de) | 2000-02-24 |
EP0656906B1 (en) | 1999-09-08 |
NZ253151A (en) | 1997-03-24 |
KR950701938A (ko) | 1995-05-17 |
FI121176B (fi) | 2010-08-13 |
HU9403516D0 (en) | 1995-02-28 |
WO1993025582A1 (en) | 1993-12-23 |
AU671837B2 (en) | 1996-09-12 |
FI20095269A (fi) | 2009-03-16 |
GR3031255T3 (en) | 1999-12-31 |
JP2003180346A (ja) | 2003-07-02 |
EP0656906A1 (en) | 1995-06-14 |
JP3500384B2 (ja) | 2004-02-23 |
HUT75824A (en) | 1997-05-28 |
CA2137551C (en) | 2002-03-26 |
JP3431922B2 (ja) | 2003-07-28 |
DK0656906T3 (da) | 1999-12-20 |
ES2135480T3 (es) | 1999-11-01 |
HU217175B (hu) | 1999-12-28 |
ATE184315T1 (de) | 1999-09-15 |
CA2137551A1 (en) | 1993-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Salmi et al. | A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans | |
Lightowlers et al. | Excretory–secretory products of helminth parasites: effects on host immune responses | |
Tsoukas et al. | Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies | |
CN102264765B (zh) | 抗muc1抗体 | |
CN101970478A (zh) | 调节SIRPα-CD47相互作用以增加造血干细胞植入以及用于此的化合物 | |
KR900006338B1 (ko) | 인체 비소형세포 폐암 및 기타 인체암 치료용 모노클로날 항체 및 항원 | |
JP3502125B2 (ja) | 形質転換細胞の抽出および培養ならびにそれらに対する抗体の製造 | |
US5866690A (en) | Detection of malignant tumor cells | |
AU637046B2 (en) | Biologically active material characterised by catabolic activity generally associated with cachexia-inducing tumours, preparations, production and uses thereof | |
CA1248892A (en) | Murine hybridoma lym-2 and diagnostic antibody produced thereby | |
Ager et al. | Lymphocyte migration in the rat | |
IBRAHIM et al. | Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis | |
Natali et al. | Tissue distribution of human Ia-like antigens | |
US6066321A (en) | Method for antagonizing vascular adhesion protein-1 (VAP-1)-mediated binding of endothelial cells to lymphocytes | |
FI121176B (fi) | Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli | |
WO1993012248A1 (en) | Ligands and binding partner for treatment and diagnosis of inflammatory conditions | |
MXPA05004563A (es) | Ligando inducible para la integrina alfa1beta1 y usos. | |
Kitabatake et al. | Immunohistochemical demonstration of proteoglycans in the skin of patients with systemic sclerosis | |
FI120496B (fi) | Lymfosyyttien sitoutumiseen vaikuttava ihmisen endoteelisolun molekyyli | |
WO1992006105A1 (en) | Antibodies and methods for diagnosis and treatment of diabetes | |
Sobel et al. | Anti-T cell monoclonal antibodies in vivo. I. Inhibition of delayed hypersensitivity but not cutaneous basophil hypersensitivity reactions. | |
Chida et al. | The detection of two surface antigens on human lung macrophages using monoclonal antibodies | |
JPH08196272A (ja) | ハイブリドーマ29d38 | |
SI8013066A8 (sl) | Postopek za pripravo monoklonalnega protitelesa okt6 | |
Kadioglu | Studies on mononuclear cell adhesion to mucosal endothelial cells in rheumatoid arthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080523 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090523 Year of fee payment: 6 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100523 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100523 Year of fee payment: 7 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110523 Year of fee payment: 8 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120523 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120523 Year of fee payment: 9 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20130523 Year of fee payment: 10 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |